Prevalence of Two Variants of BRCA2 in Women with Breast Cancer of the Hospital Día Oncológico, Encarnación, Paraguay, 2023: a Pilot Study
DOI:
https://doi.org/10.32635/2176-9745.RBC.2025v71n2.4962Keywords:
Breast Neoplasms/genetics, Genetic Diseases, Inborn, BRCA2 GeneAbstract
Introduction: Hereditary breast cancer refers to cases in which genetic predisposition plays a significant role in its development. Inherited genetic variants, particularly in the BRCA1 and BRCA2 genes, significantly increase the risk of developing breast cancer and, in some cases, ovarian cancer. Objective: To determine the prevalence of two variants of the BRCA2 gene in women with breast cancer attending the Hospital Día Oncológico in the city of Encarnación, Paraguay. Method: A pilot observational and descriptive study was conducted. The sample consisted of women aged 18 to 50 years diagnosed with breast cancer, selected through non-probabilistic convenience sampling. After obtaining informed consent, questionnaires were administered, and blood samples were collected. Subsequently, genomic sequencing techniques and genetic analysis were performed to identify BRCA2 variants. Results: A total of 11 patients participated, with a mean age of 39.45 years; six of them had a first-degree family history of cancer, and all were diagnosed with invasive breast cancer. The two analyzed BRCA2 gene variants were NM_000059.4: c.5351_5352insA and NM_000059.4: c.5681_5682insA. Conclusion: The variants investigated were not detected in the 11 women with breast cancer. A comprehensive analysis of the entire BRCA2 gene is
necessary to establish a database of genetic variants circulating in the Itapúa population.
Downloads
References
Organización Mundial de la Salud, Panamericana de la Salud [Internet]. Washigton, DC: OPAS; OMS; [sem data]. Día mundial contra el cáncer 2023: por unos cuidados más justos, 2023 [citado 2023 marzo 15]. Disponible en: https://www.paho.org/es/campanas/dia-mundial-contra-cancer-2023-por-unos-cuidados-mas-justos
Organización Mundial de la Salud, Organización Panamericana de la Salud [Internet]. Cáncer, 2024. [citado 2024 abr 25]. Disponible en: https://www.paho.org/es/temas/cancer
Ministerio de Salud Pública y Bienestar Social (PY)[Internet]. Asunción: MSPBS; ©2017. Al año se tiene un promedio de 300 nuevos casos de cáncer de mamas, 2022.[citado 2023 jul 10]. Disponible en: https://portal.ips.gov. py/sistemas/ipsportal/noticia.php?cod=747
Fernández TA, Reigosa YA. Cáncer de mama hereditario. Comunidad Salud. 2016;14(1):52-60.
Organización Mundial de la Salud. Programas Nacionales de Control contra el cáncer. Políticas y pautas para la gestión [Internet]. 2 edición. Genebra: OMS; 2004. [citado 2024 abr 25]. [Disponible en: https://www3.paho.org/hq/dmdocuments/2012/OPS-Programas-Nacionales-Cancer-2004-Esp.pdf
Organización Mundial de la Salud, Organización Panamericana de la Salud [Internet]. Cáncer de mama, 2023 [citado 2024 feb 25]. Disponible en: https://www.paho.org/es/temas/cancer-mama
Rosado-Jiménez L, Mestre-Terkemani Y, García-Aliaga Á, et al. Variantes genéticas recurrentes y priorización de variantes de significado clínico desconocido asociadas al síndrome de cáncer de mama y ovario hereditario en familias de la Región de Murcia. Adv Lab Med. 2023;4(3):288-97. doi: https://doi.org/10.1515/almed-2023-0032 DOI: https://doi.org/10.1515/almed-2023-0032
Nanda R. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American Families of European and African Ancestry. JAMA. 2005;294(15):1925-33. doi: https://doi.org/10.1001/jama.294.15.1925 DOI: https://doi.org/10.1001/jama.294.15.1925
Angeli D, Salvi S, Tedaldi G. Genetic predisposition to breast and ovarian cancers: how many and which genes to test? Int J Mol Sci. 2020;21(3):1128. doi: https://doi. org/10.3390/ijms21031128 DOI: https://doi.org/10.3390/ijms21031128
Cerretini R, Mercado G, Morganstein J, et al. Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina. Breast Cancer Res Treat. 2019;178(3):629-36. DOI: https://doi.org/10.1007/s10549-019-05411-9
Organización Mundial de la Salud, Organización Panamericana de la Salud. Planificación: Cómo mejorar el acceso a la atención para el cáncer de mama [Internet]. Genebra: OMS; OPAS; 2022. [citado 2024 feb 25]. Disponible en: https://www3.paho. org/hq/dmdocuments/2015/planificacion-mejorar-acceso.pdf
Primer3 [Internet]. Versión 4.1.0. Cambridge: Whitehead Institute for Biomedical Research; ©1996-2019. [citado 2024 feb 20]. Disponible en: https://primer3.ut.ee/
Wizard® Genomic DNA Purification Kit Technical Manual [Internet]. São Paulo: Promega Corporation; ©2025. [citado 2024 feb 20]. Disponible en: https://worldwide.promega.com/resources/protocols/technical-manuals/0/wizard-genomic-dna-purification-kit-protocol/
Bioedit [Internet]. Versión 7.7. [sem local]: Informer Technologies, Inc.; ©2025. [citado 2024 feb 20]. Disponible en: https://bioedit.software.informer.com/
PureDireX. Genomic DNA Isolation Reagent Kit [Internet]. [Sem Local]: QIAGEN; 2022. [citado 2024 feb 20]. Disponible en: https://www.bio-helix.com/uploads/product_ file/file/411/PureDireX_Protocol_PDR05-0100.pdf
BLASTN [Internet]. Versión 2.16. Bethesda: NCBI; 2023. [citado 2024 feb 20]. Disponible en: https://blast. ncbi.nlm.nih.gov/Blast.cgi
DnaSP v6 [Internet]. Barcelona: Universitat de Barcelona; 2018. [citado 2024 feb 20]. Disponible en: http://www. ub.edu/dnasp/downloadTv6.html
Adaniel C, Salinas F, Donaire J, et al. Non-BRCA1/2 variants detected in a high-risk chilean cohort with a history of breast and/or ovarian cancer. J Glob Oncol. 2019;5:1-14. DOI: https://doi.org/10.1200/JGO.18.00163
Costa E, Silva Carvalho S, Cury N, et al. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population. BMC Med Genomics. 2020;13(1):21. doi: https://doi.org/10.1186/s12920-019-0652-y DOI: https://doi.org/10.1186/s12920-019-0652-y
Zayas O, Campos L, Lugo J, et al. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case–control study. BMC Cancer. 2019;19(722):1-8. doi: https://doi.org/10.1186/s12885-019-5950-4 DOI: https://doi.org/10.1186/s12885-019-5950-4
Alvarez J. Análisis de mutaciones en BRCA1 Y BRCA2 asociadas al cáncer de mama [Internet]. 2016 [citado 2024 feb 20]. Disponible en: https://digital.csic.es/bitstream/10261/164963/1/BRCAmuta.pdf
González Ortega JM, Morales Wong MM, López Cuevas Z, et al. Factores pronósticos del cáncer de mama. Rev Cubana Cir. 2024;50(1):130-38.
Depolo J. ¿Es hereditario el cáncer de mama? Breast Cancer [Internet]. 2024 [citado 2024 dic 15]. Disponible en: https://www.breastcancer.org/es/riesgo/factores-riesgo/genetica
Rubio S, Pacheco R, Gómez A, et al. Secuenciación de nueva generación (NGS) de ADN: presente y futuro en la práctica clínica. 2020;61(2):1. doi: https://doi.org/10.11144/Javeriana.umed61-2.sngs DOI: https://doi.org/10.11144/Javeriana.umed61-2.sngs
Downloads
Published
How to Cite
Issue
Section
License
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
This work is licensed under a Creative Commons Attribution 4.0 International License.
